Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks

Table 1 Baseline demographic and clinical characteristics of the nucleoside-naive chronic hepatitis B Chinese patients

Demographic and clinical characteristics	Group A (n = 161)	Group B (n = 169)	P value
Age, yr
mean ± SD	35.16 ± 9.34	34.91 ± 9.79	0.8082
Range	19.00-62.00	19.00-64.00
Male, n (%)	116 (72.05)	134 (79.29)	0.1248
HBV DNA, log10 IU/mL	6.86 ± 1.13	6.91 ± 1.05	0. 6761
HBeAg positive
mean ± SD	7.27 ± 0.81	7.29 ± 0.71	0.8126
Range	5.00-8.66	5.02-8.47
HBeAg negative
mean ± SD	5.87 ± 1.20	6.03 ± 1.17	0.5144
Range	3.42-8.01	3.33-8.16
HBeAg status, n (%)
HBeAg negative	114 (70.81)	118 (69.82)	0.8448
HBeAg positive	47 (29.19)	51 (30.18)
Baseline HBsAg, log10 IU/mL	161 (100)	169 (100)	0.4979
HBeAb status, n (%)
HBeAg positive
HBeAb negative	12 (10.53)	16 (13.56)	0.4776
HBeAb positive	102 (89.47)	102 (86.44)
HBeAg negative
HBeAb negative	46 (97.87)	51 (100.00)	0.2236
HBeAb positive	1 (2.13)	0 (0.00)
Duration of positivity for HBV, yr
mean ± SD	10.39 ± 8.03	9.76 ± 7.22	0.4575
Range	0.00-40.00	0.50-34.00
Baseline ALT, U/L, mean ± SD	175.47 ± 92.17	180.05 ± 96.05	0.6592

HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HBeAb: Hepatitis B e antibody; ALT: Alanine transaminase; HBsAg: Hepatitis B surface antigen.